Ethical and societal aspects of IP MCQs With Answer

Ethical and Societal Aspects of IP MCQs With Answer

This set of MCQs is designed for M.Pharm students to deepen understanding of the ethical and societal implications of intellectual property (IP) as it relates to pharmaceutical validation, development, and access to medicines. Questions cover patentability, data exclusivity, compulsory licensing, traditional knowledge, biosimilars, and the ethical consequences of validation data manipulation. Each question links IP concepts to public health, regulatory practice, and social justice, helping students prepare for examinations and clinical/research decision-making. Answers are provided to facilitate self-assessment and discussion about balancing innovation incentives with equitable access to medicines.

Q1. What are the core patentability criteria generally required for a pharmaceutical invention?

• Novelty, inventive step (non-obviousness), and industrial applicability
• Commercial viability, market approval, and clinical trials completed
• Ethical approval, safety margin, and sustainability
• Trade secrecy, confidentiality, and non-disclosure agreement

Correct Answer: Novelty, inventive step (non-obviousness), and industrial applicability

Q2. Under the TRIPS Agreement, what is the minimum term of patent protection that member countries must provide?

• 10 years from grant
• 20 years from filing
• 5 years from market authorization
• 25 years from priority date

Correct Answer: 20 years from filing

Q3. What is the primary purpose of compulsory licensing in the pharmaceutical context?

• To permanently revoke a patent whenever a competitor files a lawsuit
• To allow a government to authorize use of a patented invention without the patent holder’s consent for public health needs
• To extend patent monopoly for an inventor who cannot commercialize quickly
• To create exclusive export rights for originator companies

Correct Answer: To allow a government to authorize use of a patented invention without the patent holder’s consent for public health needs

Q4. What does data exclusivity protect in drug approval processes?

• The chemical formula of a drug in perpetuity
• The right of generics to copy manufacturing processes without authorization
• Prevents regulatory agencies from relying on originator’s clinical trial data for a defined period
• Guarantees patent extension if clinical trials are delayed

Correct Answer: Prevents regulatory agencies from relying on originator’s clinical trial data for a defined period

Q5. Which practice is commonly referred to as “evergreening” in pharmaceutical patents?

• Developing completely novel chemical entities for neglected diseases
• Filing minor modifications or secondary patents to extend protection beyond the original patent term
• Voluntarily licensing patents to generics in low-income countries
• Donating patented medicines to humanitarian organizations

Correct Answer: Filing minor modifications or secondary patents to extend protection beyond the original patent term

Q6. What ethical principle underlies benefit-sharing with indigenous communities when traditional knowledge is used for drug development?

• Maximizing corporate profits irrespective of source communities
• Recognizing and compensating communities for traditional knowledge used in drug development
• Ensuring patents are always granted to corporations rather than individuals
• Preventing any disclosure of traditional use so research remains proprietary

Correct Answer: Recognizing and compensating communities for traditional knowledge used in drug development

Q7. What is meant by patent linkage in pharmaceutical regulation?

• Linking a company’s corporate tax payments to its patent portfolio
• Linking marketing approval for generics to the patent status of the originator drug to prevent premature market entry
• Linking clinical trial approval to environmental impact assessments
• Linking patent duration to international trade volumes

Correct Answer: Linking marketing approval for generics to the patent status of the originator drug to prevent premature market entry

Q8. Which ethical concern is most often raised regarding patenting of genes or naturally occurring life forms?

• That it always speeds up access to medicines
• That it commodifies life and may restrict access to essential biological materials
• That it eliminates any need for clinical validation
• That it reduces corporate investment in R&D

Correct Answer: That it commodifies life and may restrict access to essential biological materials

Q9. Why do governments offer orphan drug incentives from an ethical and societal perspective?

• To discourage research into rare diseases
• To encourage development of therapies for rare diseases where market incentives are insufficient
• To remove regulatory oversight for small-market drugs
• To make all orphan drugs automatically public domain

Correct Answer: To encourage development of therapies for rare diseases where market incentives are insufficient

Q10. How do trade secrets differ from patents in pharmaceutical validation information?

• Trade secrets require public disclosure while patents remain confidential
• Trade secrets provide potentially indefinite protection without disclosure, patents require disclosure but provide a time-limited monopoly
• Trade secrets are protected by patent offices and have fixed-term rights
• Trade secrets always give stronger enforcement rights internationally than patents

Correct Answer: Trade secrets provide potentially indefinite protection without disclosure, patents require disclosure but provide a time-limited monopoly

Q11. What is a “patent thicket” and its likely impact on pharmaceutical innovation?

• A dense forest where herbal medicines are harvested
• Multiple overlapping patents that can hinder follow-on innovation and increase costs
• A single broad patent that simplifies licensing for generics
• A governmental database for patent searches

Correct Answer: Multiple overlapping patents that can hinder follow-on innovation and increase costs

Q12. Under what circumstances can compulsory licensing be invoked to address public health needs?

• Only for cosmetic medicines with large markets
• When there is a public health emergency, national emergency, or other circumstances of extreme urgency
• Only after the patent expires
• Only if the patent holder agrees voluntarily

Correct Answer: When there is a public health emergency, national emergency, or other circumstances of extreme urgency

Q13. What are likely legal and ethical consequences if validation data are fabricated to obtain regulatory approval and patent protection?

• No consequences if the drug is profitable
• Fraud undermines trust, may lead to legal penalties, loss of regulatory approval, and invalidation of IP rights
• Automatic extension of patent term by regulatory bodies
• Only minor administrative review without criminal liability

Correct Answer: Fraud undermines trust, may lead to legal penalties, loss of regulatory approval, and invalidation of IP rights

Q14. How do TRIPS and the Doha Declaration relate to technology transfer and public health?

• TRIPS forbids any technology transfer; Doha reinforces this prohibition
• TRIPS includes provisions encouraging technology transfer; the Doha Declaration emphasizes member countries’ flexibility to protect public health
• Both documents require immediate compulsory licensing in all cases
• They only address trade tariffs and not public health

Correct Answer: TRIPS includes provisions encouraging technology transfer; the Doha Declaration emphasizes member countries’ flexibility to protect public health

Q15. What is the purpose of patent term extension mechanisms in pharmaceutical regulation?

• To permanently extend patents for any minor formulation change
• To compensate patent holders for time lost during regulatory review so they have adequate effective market exclusivity
• To shorten patent life when drugs are safe
• To eliminate need for clinical trials for generics

Correct Answer: To compensate patent holders for time lost during regulatory review so they have adequate effective market exclusivity

Q16. Why are biosimilars treated differently from small-molecule generics in IP and regulatory frameworks?

• Biosimilars are identical copies and require no data for approval
• Biosimilars are complex biological products that require additional data and comparability studies; they cannot be approved solely as identical generics
• Biosimilars are always excluded from any patent consideration
• Biosimilars never face any exclusivity barriers

Correct Answer: Biosimilars are complex biological products that require additional data and comparability studies; they cannot be approved solely as identical generics

Q17. What constitutes prior art in assessing patent novelty?

• Any private lab notebook never disclosed outside the company
• Any public disclosure (publications, patents, presentations) made before the patent filing date that can negate novelty
• Only patents filed in the same country count as prior art
• Internal memos within a company without public dissemination

Correct Answer: Any public disclosure (publications, patents, presentations) made before the patent filing date that can negate novelty

Q18. What procedural requirement is often expected before a compulsory license is granted, absent an emergency?

• No attempt to negotiate is ever required
• Efforts to obtain a voluntary license from the patent holder on reasonable terms are typically required before issuing a compulsory license
• The patent must be in force for less than one year
• The patent holder must have commercialized the product within 30 days

Correct Answer: Efforts to obtain a voluntary license from the patent holder on reasonable terms are typically required before issuing a compulsory license

Q19. Which policy approaches help balance innovation incentives with equitable access to medicines?

• Only high monopoly pricing with no safety nets
• Mechanisms such as tiered pricing, compulsory licensing, public-private partnerships, and patent pooling
• Complete abolition of IP rights for all pharmaceuticals
• Exclusive reliance on philanthropy without structural policy changes

Correct Answer: Mechanisms such as tiered pricing, compulsory licensing, public-private partnerships, and patent pooling

Q20. What is the “Bolar exemption” or experimental use exemption in relation to pharmaceutical patents?

• A rule that forbids any testing on patented compounds before patent expiry
• Permits use of patented inventions for regulatory tests and submissions so generics can prepare for market entry before patent expiry
• An obligation for originators to provide free samples to competitors
• A mechanism to extend patent life automatically for two years

Correct Answer: Permits use of patented inventions for regulatory tests and submissions so generics can prepare for market entry before patent expiry

Download